IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Iovance Biotherapeutics shares closed at $8.04, down 0.74% on the day, despite a trio of bullish analyst actions. Citizens reiterated its Market Outperform rating and raised its price target to $12, while Barclays maintained its Overweight rating and lifted its target to $19. These upgrades signal continued analyst confidence in the biotech, though the stock still slipped, possibly due to broader market pressures or profit-taking. The bullish price target hikes could provide support for the stock in upcoming sessions.

Iovance Biotherapeutics reported Q3 2026 results, posting a narrower-than-expected loss of $0.05 per share versus the $0.09 loss analysts anticipated, while revenue of $121.469 million topped the $115.982 million estimate. The company also reaffirmed its full-year 2026 sales outlook of $410 million to $420 million, bracketing the $416.263 million consensus, and filed a Form 8-K covering the quarterly results. Despite the positive earnings beat, the stock fell sharply, closing at $7.74, down 7.86% on heavy volume of over 21.7 million shares. The decline suggests the market may have already priced in the beat or reacted to other factors in the earnings call, leaving the near-term direction uncertain.

Iovance Biotherapeutics presented new clinical data at ESMO 2026 showing durable responses with its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas, including deep and lasting responses in metastatic UPS and DDLPS when given as monotherapy. Despite these bullish clinical updates, the stock closed down 2.96% at $13.78 on volume of 7.25 million shares, trading between a high of $14.20 and a low of $13.32. The positive data supports further study of lifileucel in sarcoma and may bolster the long-term regulatory outlook, though today's price action suggests the market did not reward the news immediately.